MONOCLONAL ANTIBODIES and Fc fusion proteins for therapeutic use DISTRIBUTION OF INTERNATIONAL NONPROPRIETARY NAMES BY INDICATION SOLID TUMORS RHUMATOLOGY PNEUMOLOGY Lung cancer bevacizumab Rheumatoid arthritis etanercept Allergic asthma omalizumab nivolumab infliximab Severe eosinophilic asthma mepolizumab necitumumab adalimumab reslizumab atezolizumab rituximab Colorectal cancer bevacizumab abatacept TRANSPLANTATION cetuximab tocilizumab Transplant rejection basiliximab panitumumab certolizumab pegol belatacept aflibercept golimumab Graft versus host disease inolimomab Bladder cancer atezolizumab Psoriatic arthritis etanercept Breast cancer trastuzumab adalimumab OPHTALMOLOGY bevacizumab infliximab Age related macular ranibizumab pertuzumab golimumab degeneration aflibercept trastuzumab entansine ustekinumab bevacizumab Gastric cancer trastuzumab certolizumab pegol Macular edema ranibizumab ramucirumab secukinumab aflibercept Head and neck cancer cetuximab Ankylosing spondylitis infliximab Myopic choroidal ranibizumab Ovarian cancer bevacizumab etanercept neovascularization aflibercept Fallopian tube cancer bevacizumab adalimumab Cervical cancer bevacizumab golimumab HAEMOSTASIS AND THROMBOSIS Kidney cancer bevacizumab certolizumab pegol nivolumab secukinumab Haemophilia A efmoroctocog α Melanoma ipilimumab Juvenile arthritis etanercept Haemophilia B eftrenonacog α nivolumab adalimumab Reversal of dabigatran idarucizumab Idiopathic thrombocytopenic pembrolizumab abatacept romiplostim Neuroblastoma dinutuximab tocilizumab purpura Malignant ascites catumaxomab canakinumab Unstable angina Bone metastasis denosumab Gouty arthritis canakinumab Percutaneous coronary abciximab Soft tissue sarcoma olaratumab Osteoporosis denosumab intervention Merkel cell carcinoma avelumab GASTROENTEROLOGY ENDOCRINOLOGY AND METABOLISM HAEMATOLOGIC DISEASES Crohn’s disease infliximab Type 2 diabetes dulaglutide Hodgkin’s lymphoma brentuximab vedotin adalimumab INFECTIOUS DISEASES nivolumab vedolizumab Non-Hodgkin’s lymphomas rituximab Prevention of respiratory ustekinumab palivizumab ibritumomab tiuxetan Ulcerative colitis infliximab syncytial virus infection brentuximab vedotin adalimumab Anthrax infection raxibacumab inotuzumab ozogamicine golimumab obiltoxaximab obinutuzumab vedolizumab Prevention of bezlotoxumab Chronic lymphocytic leukaemia rituximab Clostridium difficile infections alemtuzumab NEUROLOGY GENETIC DISEASES ofatumumab Multiple sclerosis natalizumab obinutuzumab alemtuzumab Cryopyrinopathies canakinumab Acute lymphocytic leukaemia blinatumomab Atypical hemolytic daclizumab eculizumab inotuzumab ozogamicine uremic syndrome Acute myeloid leukaemia gemtuzumab ozogamicine DERMATOLOGY evolocumab Familial hypercholesterolemias Multiple myeloma daratumumab alirocumab elotuzumab Psoriasis etanercept Paroxysmal nocturnal infliximab eculizumab haemoglobinuria adalimumab ustekinumab IMMUNOLOGY secukinumab ixekizumab Systemic lupus erythematosus belimumab Chronic spontaneous urticaria omalizumab Castleman’s disease siltuximab 03/2017 Université François-Rabelais - SID’com - Alexandra Louault - SID’com Alexandra François-Rabelais 03/2017 Université.